Back to LCT Homepage Targeting Huntington's Disease, Stroke, Type 1 Diabetes and Haemophilia
Information about LCT Living Cell Technologies
LCT - Living Cell Technologies
News updates: Subscribe
Unsubscribe


July 22, 2008
LCT Reports Clinical Benefits
July 17, 2008
LCT Hosts Seminar of World Leaders
July 14, 2008
LCT Quarterly Newsletter
July 11, 2008
Transcript of LCT interview with The Wall Street
June 26, 2008
LCT Informed of Progress for Diabetes Clinical Trial
 

Research

LCT is actively working to increase the awareness and understanding of diabetes, haemophilia, Huntington’s disease and stroke.

Diabetes is a chronic disease characterised by high blood glucose levels resulting from the body not producing insulin or using it properly. more

Haemophilia is a blood clotting disorder in which one of the essential clotting factors is deficient. more

Huntington’s disease is an inherited neurological condition. It is a degenerative brain disease with the symptoms gradually worsening over time. more

Stroke (also known as cerebrovascular disease) occurs when the supply of blood to the brain is suddenly disrupted. more

 



LCT - Living Cell Technologies
What is xenotransplantation?
The use of living animal cells, tissues or organs in human therapeutics. >more

What is DiabeCell?
DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. >more

What is NeurotrophinCell?
A choroid plexus (brain) cell product with the potential to treat diseases of the nervous system such as Huntington's disease and stroke. >more

What is LCT's encapsulation technology?
The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form capsules which eliminate the
need for toxic immunosuppressant drugs and allow the release of beneficial factors.
>more
   
graphic design and website design - PDF Communications Ltd